Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

Arrieta, Óscar; Cardona, Andrés Felipe; Bramuglia, Guillermo F.; Gallo, Aly; Campos‐Parra, Alma D.; Serrano, Sílvia; Castro, Marcelo; Avilés, Alejandro; Amorín, Edgar; Kirchuk, Ricardo; Cuello, Mauricio; Borbolla, José R.; Riemersma, Omar; Becerra, Henry; Rosell, Rafael

doi:10.1097/jto.0b013e31822f655f

Cited by 109 publications

(109 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unexpectedly, we discovered that US Hispanics seem to have a lower frequency of actionable EGFR mutations in their lung cancers than those reported in Latin America. Arrieta et al, 18 in a study of 1150 patients in Latin America, found that the frequency of EGFR mutations in non-small cell carcinoma of the lung was 33.2% overall, including 19.3% in Argentina, 24.8% in Colombia, 31.2% in Mexico, and 67.0% in Peru. Of note, these authors' findings may be skewed because of the disproportionate inclusion of nonsmokers and women.…”

Section: Resultsmentioning

confidence: 99%

“…COMMENT The frequency of the EGFR mutations in different populations is well documented. [16][17][18][19] For example, the mutation rate is higher in Asians and female nonsmokers. 20 However, the EGFR mutation rate in lung adenocarcinomas among the US Hispanic population has not been previously investigated to our knowledge.…”

Section: Resultsmentioning

confidence: 99%

“…Of note, the frequency of EGFR mutations in non-small cell carcinoma of the lung has been reported to be 33.2% in Latin American countries overall, which is similar to the Asian population. 18,19 The objective of this study was to determine the prevalence and type of EGFR mutations that occur in adenocarcinomas among the US Hispanic population.…”

mentioning

confidence: 99%

See 2 more Smart Citations

EGFRMutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

Zhang

McQuitty

Olsen

et al. 2014

Archives of Pathology & Laboratory Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

EGFRMutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

Zhang

McQuitty

Olsen

et al. 2014

Archives of Pathology & Laboratory Medicine

View full text Add to dashboard Cite

“…In the first of these, 15 650 non-small cell lung cancer specimens from Argentina, Colombia, Peru, and Mexico had a KRAS mutation frequency of 16.6% (n ¼ 108). In the second study, 16 KRAS mutation frequency among 206 non-small cell lung cancer specimens from Brazilian patients was 14.6% (n ¼ 30).…”

Section: Commentmentioning

confidence: 99%

“…5 Oncogenic mutations in EGFR have been found in non-small cell lung cancers in only 19% of African Americans 6-9 and 17% of non-Hispanic whites, 10,11 compared with 66% of Asians [10][11][12][13][14] and 33% of Hispanics. 15,16 Furthermore, EML4-ALK rearrangements are reported in approximately 6% to 7% of Asians with lung adenocarcinoma, compared with only 1% to 2% of non-Hispanic white patients. [17][18][19][20] Targeted therapies are available for both biomarkers, and standard of care requires testing all lung adenocarcinomas for EGFR mutations and EML4-ALK rearrangements.…”

mentioning

confidence: 99%

Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients

McQuitty

Zhang

Hendrickson

et al. 2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Lung cancer is the leading cause of cancer deaths in the United States and worldwide. Biomarker testing is critical to personalized therapy in lung adenocarcinoma and has been extensively investigated in nonHispanic whites, Asians, and African Americans. However, little information addresses the underlying genetic changes in lung adenocarcinoma among Hispanic patients in the United States.Objective.-To identify targetable biomarkers other than EGFR and EML4-ALK in Hispanic patients with lung adenocarcinoma.Design.-We tested DNA extracted from 85 lung adenocarcinoma specimens collected from 40 Hispanic and 43 non-Hispanic white patients for previously reported mutations in KRAS, MET, BRAF, mTOR, STAT3, JAK2, PIK3CA, AKT1 through AKT3, and PTEN with a custom Sequenom massARRAY assay (Sequenom, San Diego, California).Results.-Mutations in KRAS were identified in 11 cases (13%; 6 Hispanic [7%], 5 non-Hispanic white [6%]) and had no correlation with sex, age, or smoking history. Mutations in PIK3CA were identified in 2 of the 40 Hispanic patients (5%), including one patient (2.5%) with a concurrent KRAS mutation. The tumors were wild type for all other genes tested.Conclusions.-Targetable biomarkers other than EGFR and EML4-ALK were identified in 7 of the 40 Hispanic patients (18%) and 5 of the 43 non-Hispanic white patients (12%), suggesting a similar mutational frequency. Our highly multiplexed genotyping assay detected actionable mutations in 14% (12 of 83) more patients than would have been identified by EGFR and EML4-ALK testing alone.

show abstract

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era. Methods The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses. Results A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05). Conclusion Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.

show abstract

Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

Abstract: Our findings suggest that the frequency of EGFR mutations in Latin America lies between that of Asian and Caucasian populations and therefore support the genetic heterogeneity of NSCLC around the world.

Cited by 109 publications

References 15 publications

EGFRMutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

EGFRMutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients

Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

Contact Info

Product

Resources

About